Blekher Tanya, Weaver Marjorie, Rupp Jason, Nichols William C, Hui Siu L, Gray Jacqueline, Yee Robert D, Wojcieszek Joanne, Foroud Tatiana
Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202-5251, USA.
Parkinsonism Relat Disord. 2009 Aug;15(7):506-10. doi: 10.1016/j.parkreldis.2009.01.002. Epub 2009 Feb 10.
To evaluate quantitative measures of saccades as possible biomarkers in early stages of Parkinson disease (PD) and in a population at-risk for PD.
The study sample (n=68) included mildly to moderately affected PD patients, their unaffected siblings, and control individuals. All participants completed a clinical evaluation by a movement disorder neurologist. Genotyping of the G2019S mutation in the LRRK2 gene was performed in the PD patients and their unaffected siblings. A high resolution, video-based eye tracking system was employed to record eye positions during a battery of visually guided, anti-saccadic (AS), and two memory-guided (MG) tasks. Saccade measures (latency, velocity, gain, error rate, and multiple step pattern) were quantified.
PD patients and a subgroup of their unaffected siblings had an abnormally high incidence of multiple step patterns (MSP) and reduced gain of saccades as compared with controls. The abnormalities were most pronounced in the more challenging version of the MG task. For this task, the MSP measure demonstrated good sensitivity (87%) and excellent specificity (96%) in the ability to discriminate PD patients from controls. PD patients and their siblings also made more errors in the AS task.
Abnormalities in eye movement measures appear to be sensitive and specific measures in PD patients as well as a subset of those at-risk for PD. The inclusion of quantitative laboratory testing of saccadic movements may increase the sensitivity of the neurological examination to identify individuals who are at greater risk for PD.
评估眼球扫视的定量指标,看其是否有可能作为帕金森病(PD)早期阶段以及PD高危人群的生物标志物。
研究样本(n = 68)包括轻度至中度受影响的PD患者、其未受影响的兄弟姐妹以及对照个体。所有参与者均由运动障碍神经科医生进行临床评估。对PD患者及其未受影响的兄弟姐妹进行LRRK2基因G2019S突变的基因分型。采用高分辨率、基于视频的眼动追踪系统,在一系列视觉引导、反扫视(AS)和两项记忆引导(MG)任务中记录眼睛位置。对眼球扫视指标(潜伏期、速度、增益、错误率和多步模式)进行量化。
与对照组相比,PD患者及其未受影响的兄弟姐妹亚组的多步模式(MSP)发生率异常高,且眼球扫视增益降低。这些异常在MG任务更具挑战性的版本中最为明显。对于该任务,MSP指标在区分PD患者与对照组的能力方面表现出良好的敏感性(87%)和出色的特异性(96%)。PD患者及其兄弟姐妹在AS任务中也出现了更多错误。
眼球运动指标异常似乎是PD患者以及一部分PD高危人群的敏感且特异的指标。纳入眼球扫视运动的定量实验室检测可能会提高神经学检查的敏感性,以识别出患PD风险更高的个体。